ImmunityBio

Biotechnology company specializing in the development of novel immunotherapies for advanced cancers and infectious diseases. ImmunityBio differentiates itself with key products such as the IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and next-generation adenovirus-vectored anti-cancer vaccines, which aim to enhance the immune system's ability to combat serious diseases. The company's primary target demographic includes patients suffering from advanced cancers and infectious diseases, as well as healthcare providers seeking innovative treatment options.